321 results on '"Overkamp, Friedrich"'
Search Results
2. Return of individual genomic research results within the PRAEGNANT multicenter registry study
3. A look into the neighboring discipline: eHealth in oncology
4. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
5. Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
6. Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom
7. Digitalisierung in der Onkologie: Chancen und Nutzen in der klinischen Praxis
8. Unternehmer mit Schwerpunkt Digitalisierung
9. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry
10. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
11. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
12. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
13. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
14. Hirntumoren
15. Translational highlights in breast cancer research and treatment: recent developments with clinical impact
16. Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network
17. Return of individual genomic research results within the PRAEGNANT multicenter registry study
18. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
19. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients
20. Survival after secondary liver resection in metastatic colorectal cancer : Comparing data of three prospective randomized European trials ( LICC , CELIM , FIRE ‐3)
21. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials ( LICC , CELIM , FIRE ‐3)
22. Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation
23. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
24. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients
25. Patientsʼ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
26. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
27. Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
28. Update Mammakarzinom 2020 Teil 3 – frühes Mammakarzinom
29. Update Mammakarzinom 2020 Teil 4 – fortgeschrittenes Mammakarzinom
30. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
31. Additional file 1 of Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
32. Additional file 2 of Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
33. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
34. Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
35. Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer
36. (Fehl-)Steuerung im Gesundheitswesen
37. Das ökonomische Dilemma
38. Klinische Studien in der Onkologie - 2013 und zukünftig
39. Vorwort
40. Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
41. Umsetzung integrativer Konzepte - eine Bestandsaufnahme
42. Vorwort
43. Vorwort
44. Diagnosis and therapy of tumors with NTRK gene fusion
45. Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
46. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
47. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
48. Update Breast Cancer 2020 Part 3 – Early Breast Cancer
49. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
50. Update Mammakarzinom 2020 Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.